Heat Shock Proteins in Cardiovascular Disease: A New Therapeutic Target

Cardiology in Review

Volumn 12, Issue 1, 2004, Pages 26-30

  Gupta, Mita ^a   Vavasis, Christos ^b   Frishman, William H ^c,d  

^a RHODE ISLAND HOSPITAL   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Heat shock proteins; Ischemia; Vascular disease

Indexed keywords

HEAT SHOCK PROTEIN; TRANSCRIPTION FACTOR;

AORTA ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CORONARY ARTERY DISEASE; DRUG TARGETING; GENETIC TRANSFECTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SAFETY; STRESS;

ANIMALS; CARDIOVASCULAR DISEASES; HEAT-SHOCK PROTEINS; HEAT-SHOCK RESPONSE; HUMANS;

EID: 0347510815     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000090894.70619.fa     Document Type: Review

References (31)

1. Snoeckx LHEH, Cornelussen RN, Van Nieuwenhoven FA, et al. Heat shock proteins and cardiovascular pathophysiology. Physiol Rev. 2001;81:1461-1497.
2. Yellon DM, Latchman DS. Stress proteins and myocardial protection. J Mol Cell Cardiol. 1992;24:113-124.
3. Knowlton AA. The role of heat shock proteins in the heart. J Mol Cell Cardiol. 1995;27:121-131.
4. Frostegard J, Lemne C, Andersson B, et al. Association of serum antibodies to heat shock protein 65 with borderline hypertension. Hypertension. 1997;29:40-44.
5. Pockley AG, Wu R, Lemne C, et al. Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension. 2000;36:303-307.
6. Schäfler AE, Kirmanoglou K, Pecher P, et al. Overexpression of heat shock protein 60/10 in myocardium of patients with chronic atrial fibrillation. Ann Thorac Surg. 2002;74:767-770.
7. Zhu J, Quyyumi AA, Rott D, et al. Antibodies to human heat shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune components of atherogenesis. Circulation. 2001;103:1071-1075.
8. Xu Q, Schett G, Perschinka H, et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation. 2000;102:14-20.
9. Prohaszka Z, Duba J, Horvath L, et al. Comparative study on antibodies to human and bacterial 60 kDa heat shock proteins in a large cohort of patients with coronary heart disease and healthy subjects. Eur J Clin Invest. 2001;31:285-292.
10. Currie RW. Effects of ischemia and perfusion temperature on the synthesis of stress-induced (heat shock) proteins in isolated and perfused rat hearts. J Mol Cell Cardiol. 1987;19:795-808.
11. Martin JL, Mestril R, Hilal-Dandan R, et al. Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation. 1997;96:4343-4348.
12. Currie RW, Karmazyn M, Kloc M, et al. Heat shock response is associated with enhanced postischemic ventricular recovery. Circ Res. 1988;63:543-549.
13. Latchman DS. Heat shock proteins and cardiac protection. Cardiovasc Res. 2001;51:637-646.
14. Hutter MM, Sievers RE, Barbosa V, et al. Heat shock protein induction in rat hearts. A direct correlation between the amount of heat shock protein induced and the degree of myocardial protection. Circulation. 1994;89:355-360.
15. Currie RW. Heat-shock response and limitation of tissue necrosis during occlusion/reperfusion in rabbit hearts. Circulation. 1993;87:963-971.
16. Suzuki K, Murtuza B, Sammut IA, et al. Heat shock protein 72 enhances manganese superoxide dismutase activity during myocardial ischemia-reperfusion injury, associated with mitochondrial protection and apoptosis reduction. Circulation. 2002;106(suppl I):I270-I276.
17. Patel HH, Hsu A, Gross GJ. Attenuation of heat shock-induced cardioprotection by treatment with the opiate receptor antagonist naloxone. Am J Physiol Heart Circ Physiol. 2002;282:H2011-H2017.
18. Pockley AG. Heat shock proteins, inflammation, and cardiovascular disease. Circulation. 2002;105:1012-1017.
19. Wysocki J, Karawajczyk B, Gorski J, et al. Human heat shock protein 60 (409-424) fragment is recognized by serum antibodies of patients with acute coronary syndromes. Cardiovasc Pathol. 2002;11:238-243.
20. Xu Q, Willeit J, Marosi M, et al. Association of serum antibodies to heat shock protein 65 with carotid atherosclerosis. Lancet. 1993;341:255-259.
21. Veres A, Fust G, Smieja M, et al. Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events. Circulation. 2002;106:2775-2880.
22. George J, Greenberg S, Barshack I, et al. Accelerated intimal thickening in carotid arteries of balloon-injured rats after immunization against heat shock protein 70. J Am Coll Cardiol. 2001;38:1564-1569.
23. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:1547-1559.
24. Vigh L, Literati PN, Ibolya H, et al. Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. Nat Med. 1997;3:1150-1154.
25. Jednakovits A, Ferdinandy P, Jaszlits L, et al. In vivo and in vitro acute cardiovascular effects of bimoclomol. Gen Pharmacol. 2000;34:363-369.
26. Lubbers N, Polakowski J, Wegner C, et al. Oral bimoclomol elevates heat shock protein 70 and reduces myocardial infarct size in rats. Eur J Pharmacol. 2002;435:79-83.
27. Polakowski J, Wegner C, Cox B. Bimoclomol elevates heat shock protein 70 and cytoprotects rat neonatal cardiomyocytes. Eur J Pharmacol. 2002;435:73-77.
28. Clinical Development: Bimoclomol (Biorex-Research & Development Focus web site). Available at: http://www.biorex.hu/e_r&df_c.htm. Accessed January 10, 2003.
29. Emiliusen L, Gough M, Bateman A, et al. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory components. Gene Ther. 2001;8:987-998.
30. Christians ES, Yan L-J, Benjamin IJ. Heat shock factor 1 and heat shock proteins: critical partners in protection against acute cell injury. Crit Care Med. 2002;30(suppl):S43-S50.
31. Frishman WH, Retter A, Mobati D, et al. Innovative drug targets for treating cardiovascular disease: adhesion molecules, cytokines, neuropeptide Y, calcineurin, bradykinin, urotensin, and heat shock protein. In: Frishman WH, Sonnenblick EH, Sica DA, eds. . Cardiovascular Pharmacotherapeutics. 2nd ed. New York, NY: McGraw Hill; 2003;705-739.